Halozyme Therapeutics, Inc. Earnings

Halozyme Therapeutics, Inc.’s revenue jumped 22.12% since last year same period to $354.26Mn in the Q3 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 8.76% jump in its revenue since last 3-months.

Halozyme Therapeutics, Inc.’s net profit jumped 27.89% since last year same period to $175.23Mn in the Q3 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 6.09% jump in its net profits since last 3-months.

Halozyme Therapeutics, Inc.’s net profit margin jumped 4.72% since last year same period to 49.46% in the Q3 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated -2.45% fall in its net profit margins since last 3-months.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 1.76 - a -7.37% fall from last quarter’s estimates.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 1.76.

Halozyme Therapeutics, Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2026. This indicates that the Halozyme Therapeutics, Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.